Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ravidasvir - Presidio Pharmaceuticals/XTL Biopharmaceuticals

Next Previous
Drug Profile

Ravidasvir - Presidio Pharmaceuticals/XTL Biopharmaceuticals

Alternative Names: ASC-16; Asclevir; BI-238630; C5; PPI-668

Latest Information Update: 28 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XTL Biopharmaceuticals
  • Developer Ascletis; Drugs for Neglected Diseases Initiative Foundation; European Egyptian Pharmaceutical Industries; Ministry of Public Health (Thailand); Pharco Corporation; Presidio Pharmaceuticals
  • Class Antivirals; Benzimidazoles; Carbamates; Naphthalenes; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C
  • Phase II/III COVID 2019 infections

Most Recent Events

  • 28 Mar 2023 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in Australia (PO, Tablet)
  • 28 Jun 2022 Launched for Hepatitis C (Combination therapy, Treatment-naive) in China (PO)
  • 29 Jul 2021 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top